Abstract
BackgroundWe previously developed a robust prognostic model (GS model) to predict the survival outcome of patients with advanced pancreatic cancer (APC) receiving palliative chemotherapy with gemcitabine plus S‐1 (GS). This study aimed to validate the application of the GS model in APC patients receiving chemotherapy other than the GS regimen.Patients and methodsWe retrospectively analyzed 727 APC patients who received first‐line palliative chemotherapy other than the GS regimen between 2010 and 2016 at four institutions in Taiwan. The patients were categorized into three prognostic groups based on the GS model for comparisons of survival outcome, best tumor response, and in‐group survival differences with monotherapy or combination therapy.ResultsThe median survival times for the good, intermediate, and poor prognostic groups were 13.4, 8.4, and 4.6 months, respectively. The hazard ratios for the comparisons of intermediate and poor to good prognostic groups were 1.51 (95% confidence interval [CI]), 1.22‐1.88, P < .001) and 2.84 (95% CI, 2.34‐3.45, P < .001). The best tumor responses with either partial response or stable disease were 57.5%, 40.4%, and 17.2% of patients in the good, intermediate, and poor prognostic groups (P < .001), respectively. For patients in the good prognostic group, first‐line chemotherapy with monotherapy and combination therapy had similar median survival times (13.8 vs 12.9 months, P = .26), while combination therapy showed a better median survival time than monotherapy in patients in the intermediate and poor prognostic groups (8.5 vs 8.0 months, P = .038 and 5.7 vs 3.7 months, P = .001, respectively).ConclusionThe results of our study supported the application of the GS model as a general prognostic tool for patients with pancreatic cancer receiving first‐line palliative chemotherapy with gemcitabine‐based regimens.
Highlights
Pancreatic cancer is one of the most lethal cancers worldwide; as more than 80% of patients present with unresectable disease at diagnosis,[1,2] palliative chemotherapy is the standard of care.[3]
We previously developed a robust prognostic model 11 to predict survival outcomes of advanced pancreatic cancer (APC) patients who received first‐line palliative chemotherapy with gemcitabine plus S‐1 (GS regimen).[12]
Our current study extended the clinical application of the GS model for survival prediction regardless of the chemotherapy regimen used for the treatment of patients with APC
Summary
Pancreatic cancer is one of the most lethal cancers worldwide; as more than 80% of patients present with unresectable disease at diagnosis,[1,2] palliative chemotherapy is the standard of care.[3]. The patients were categorized into three prognostic groups based on the GS model for comparisons of survival outcome, best tumor response, and in‐group survival differences with monotherapy or combination therapy. For patients in the good prognostic group, first‐line chemotherapy with monotherapy and combination therapy had similar median survival times (13.8 vs 12.9 months, P = .26), while combination therapy showed a better median survival time than monotherapy in patients in the intermediate and poor prognostic groups (8.5 vs 8.0 months, P = .038 and 5.7 vs 3.7 months, P = .001, respectively). Conclusion: The results of our study supported the application of the GS model as a general prognostic tool for patients with pancreatic cancer receiving first‐line palliative chemotherapy with gemcitabine‐based regimens
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
